The study, conducted by the Mayo Clinic, Johns Hopkins School of Medicine and medical device manufacturer TYRX, found patients with cardiac device-associated infections had triple the length of hospital stay, 55-118 percent higher hospitalization costs, 8-11 times the rate of in-hospital mortality and twice the mortality a year after admission compared to patients implanted with a pacemaker or defibrillator who did not contract an infection.
Read the TYRX release on infections associated with cardiac devices (pdf).
Read more coverage on infection control:
– CDC Updates Bloodstream Infection Prevention Guidelines
– Hospital Nabs Top Recognition Despite Criticism for High Infection Rates, Fraud
– Dr. Edo McGowan Responds to Study Indicating MRSA Infection May Be Seasonal
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.